Spironolactone in the treatment of polycystic ovary syndrome

@article{Armanini2016SpironolactoneIT,
  title={Spironolactone in the treatment of polycystic ovary syndrome},
  author={Decio Armanini and Alessandra Andrisani and Luciana Bordin and Chiara Sabbadin},
  journal={Expert Opinion on Pharmacotherapy},
  year={2016},
  volume={17},
  pages={1713 - 1715}
}
Charles Masayuki Kagawa passed away on 9 May 2015 at the age of 92. He is considered the father of SP [1]. From 1957, he studied a steroid compound (Aldactone-SC9420) which caused sodium depletion and moderate retention of potassium depending on the action of the mineralocorticoids. In 1963, Janigan showed cytoplasmatic inclusions, called ‘SP bodies’, in the glomerulosa of patients treated with SP, hypothesizing a direct effect on the adrenocortical hormone secretion. In 1959, Kagawa reported… Expand
Spironolactone reversed hepato-ovarian triglyceride accumulation caused by letrozole-induced polycystic ovarian syndrome: tissue uric acid—a familiar foe
TLDR
Taken together, spironolactone reversed the PCOS-induced ovarian and hepatic tissue damage by suppressing tissue UA and TG accumulation and attenuated the elevated testosterone in the LET-induced PCOS model. Expand
Licorice: From Pseudohyperaldosteronism to Therapeutic Uses
TLDR
Some interesting therapeutic uses of licorice are linked to its anti-androgen and estrogen-like activity, especially in the treatment of polycystic ovary syndrome (PCOS) in conjunction with spironolactone therapy. Expand
Very low dose spironolactone protects experimentally-induced polycystic ovarian syndrome from insulin-resistant metabolic disturbances by suppressing elevated circulating testosterone.
TLDR
Analysis of the physical, biochemical and histological evidences shows that the protective effect of this very low dose spironolactone may be through its anti-androgenic mechanism. Expand
Female Androgenetic Alopecia: An Update on Diagnosis and Management
TLDR
An update on FAGA is provided and a guideline on diagnosis and management of this frequent hair disease, not always easily recognizable from cicatricial alopecias with a similar distribution is created. Expand
Uterine fibroids and risk of hypertension: Implication of inflammation and a possible role of the renin‐angiotensin‐aldosterone system
TLDR
A certain role of progesterone and PR in UF pathogenesis but not in hypertension, progestersone being a mineralocorticoid receptor (MR) antagonist and PRα and PRβ, compared to the surrounding myometrium, are suggested. Expand
Aldosterone in Gynecology and Its Involvement on the Risk of Hypertension in Pregnancy
TLDR
The aim of this mini-review is to report the possible involvement of aldosterone in all these gynecological conditions, suggesting different pathogenetic mechanisms and new target treatments of MR blockers for these diseases. Expand
A Review of hormone-based therapies to treat adult acne vulgaris in women
TLDR
Combined oral contraceptive medications and spironolactone as adjuvant and monotherapies are safe and effective to treat women with adult acne, however, appropriate clinical examinations, screening, and individual risk assessments particularly for venous thromboembolism risk must be conducted prior to initiating therapy. Expand
High‐dose spironolactone lacks effectiveness in treatment of fibromyalgia (RCT)
Spironolactone (SPL) is a reversible mineralocorticoid receptor (MR) and androgen receptor (AR) antagonist which attracts pharmacotherapeutic interest not only because of its beneficial effects inExpand
The Use of Antihypertensive Drugs as Coadjuvant Therapy in Cancer
TLDR
This review examines the preclinical and clinical evidence for utilizing antihypertensive agents in the treatment of cancer and some of these drugs have exhibited pharmacological properties useful for the Treatment of cancer, rendering them candidates for drug repurposing. Expand
Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS
TLDR
Overall, PCOS management remains focused on specific targets including assessment and treatment of cardiometabolic risk, according to disease phenotypes. Expand
...
1
2
...

References

SHOWING 1-10 OF 21 REFERENCES
The story of spironolactones from 1957 to now: from sodium balance to inflammation.
TLDR
Considering all the benefits of MR-antagonists, their use should be reconsidered not only for the treatment but also for the prevention of many clinical situations. Expand
Treatment of polycystic ovary syndrome with spironolactone plus licorice.
TLDR
In patients with PCOS the mineralocorticoid properties of licorice can reduce the prevalence of side effects related to the diuretic activity of spironolactone. Expand
Syndromes that Mimic an Excess of Mineralocorticoids
Pseudohyperaldosteronism is characterized by a clinical picture of hyperaldosteronism with suppression of renin and aldosterone. It can be due to endogenous or exogenous substances that mimic theExpand
Spontaneous resolution of idiopathic aldosteronism after long-term treatment with potassium canrenoate.
To the Editor: Primary aldosteronism (PA) is the most common form of secondary hypertension. The prevalence of PA is raised from 1% to 3% to 10% to 15% because of the introduction of the uprightExpand
Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI
TLDR
Intermenstrual abnormalities may represent the low estrogen impregnation of endometrium due to SP, whose mechanism is complex, involving several factors, such as the effects of some metabolites of SP on estradiol and progesterone production, on their receptors, and the individual metabolism of SP in vivo. Expand
Spironolactone in the treatment of polycystic ovary syndrome: Effects on clinical features, insulin sensitivity and lipid profile
TLDR
The data show that long-term treatment with spironolactone exerts no negative effects on lipoprotein profile and glucose metabolism; more relevant beneficial effects on glucose and lipid metabolism were observed when the antiandrogen was associated with weight loss in overweight PCOS women. Expand
A novel use of spironolactone: treatment of hirsutism.
TLDR
The data suggest that the antiandrogenic properties of spironolactone render it a suitable agent in the treatment of hirsutism. Expand
Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs
TLDR
Both canrenone and hydrochlorothiazide can enhance the effect of treatment with ACE inhibitors and angiotensin II receptor blockers on microalbuminuria, but ALDO receptor blockers are more active. Expand
Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.
Polycystic ovary syndrome (PCOS) is now recognized as an important metabolic as well as reproductive disorder conferring substantially increased risk for type 2 diabetes. Affected women have markedExpand
Polycystic ovary syndrome: Implications of measurement of plasma aldosterone, renin activity and progesterone
TLDR
The increase of plasma aldosterone, ARR and blood pressure inPCOS compared with controls is consistent with an increased mineralocorticoid effector mechanism in PCOS; prolonged therapy with spironolactone could counteract both the hyperandrogenism and reduce future cardiovascular risk. Expand
...
1
2
3
...